Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,275,498
  • Shares Outstanding, K 59,950
  • Annual Sales, $ 1,488 M
  • Annual Income, $ 396,830 K
  • 36-Month Beta 1.00
  • Price/Sales 5.53
  • Price/Cash Flow 15.42
  • Price/Book 3.34

Price Performance

See More
Period Period Low Period High Performance
1-Month
128.58 +7.36%
on 11/07/17
143.86 -4.05%
on 10/23/17
-6.01 (-4.17%)
since 10/20/17
3-Month
128.58 +7.36%
on 11/07/17
155.85 -11.43%
on 09/18/17
-8.70 (-5.93%)
since 08/22/17
52-Week
99.28 +39.04%
on 12/07/16
163.75 -15.70%
on 04/28/17
+29.21 (+26.84%)
since 11/22/16

Most Recent Stories

More News
Corporate News Blog - RXi Pharma Collaborates with Gustave Roussy, Europe's Leading Cancer Centre

Research Desk Line-up: Jazz Pharma Post Earnings Coverage

RXII : 0.65 (+4.00%)
JAZZ : 138.04 (+0.62%)
Featured Company News - Adaptimmune Outlines Study Designs for Two T-Cell Clinical Trials - MAGE-A4 and NY-ESO SPEAR

Research Desk Line-up: Jazz Pharma Post Earnings Coverage

JAZZ : 138.04 (+0.62%)
ADAP : 8.11 (+2.85%)
GSK : 35.06 (+0.72%)
Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

Jazz Pharmaceuticals plc today announced that the company will be webcasting its corporate presentations at three upcoming investor conferences.

JAZZ : 138.04 (+0.62%)
Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at three upcoming investor conferences.

JAZZ : 138.04 (+0.62%)
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.

JAZZ : 138.04 (+0.62%)
EBS : 40.87 (+3.94%)
IMGN : 5.82 (+0.87%)
EXEL : 26.13 (+0.31%)
Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results

Total Revenues Increased 10% to $412 Million

JAZZ : 138.04 (+0.62%)
Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2017 and updated financial guidance for 2017.

JAZZ : 138.04 (+0.62%)
Jazz Pharmaceuticals Submits Vyxeos(TM) Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia

Vyxeos granted accelerated assessment review status from European Medicines Agency's Committee for Medicinal Products for Human Use

JAZZ : 138.04 (+0.62%)
Jazz Pharmaceuticals Submits Vyxeos(TM) Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)...

JAZZ : 138.04 (+0.62%)
Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting

Nineteen abstracts accepted for three Jazz hematology/oncology products

JAZZ : 138.04 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

2nd Resistance Point 141.97
1st Resistance Point 140.00
Last Price 138.04
1st Support Level 136.74
2nd Support Level 135.45

See More

52-Week High 163.75
Fibonacci 61.8% 139.12
Last Price 138.04
Fibonacci 50% 131.51
Fibonacci 38.2% 123.91
52-Week Low 99.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart